Boltz-1: A new open-source AI tool for drug discovery
MIT's new open-source AI model, Boltz-1, could transform drug discovery by accurately predicting protein structures, offering global access to researchers.
List view / Grid view
MIT's new open-source AI model, Boltz-1, could transform drug discovery by accurately predicting protein structures, offering global access to researchers.
Researchers at the University of Chicago have revealed the complete structure of adhesion GPCRs, uncovering new activation mechanisms that could lead to more targeted drug treatments.
New studies highlight the potential of automated blood exchange to improve outcomes for sickle cell disease patients.
A breakthrough in molecular imaging could transform how doctors target solid tumours, offering more personalised and effective treatment options.
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
Refeyn's new software automates mass photometry workflows, delivering faster and more consistent results for bioanalytical applications.
Novartis has teamed up with PTC Therapeutics to develop PTC518, a groundbreaking treatment that targets the cause of Huntington's disease, offering new hope for patients.
Scientists have decoded the 3D structure of a key enzyme linked to Alzheimer's disease. This breakthrough opens up new possibilities for targeted drug development and better treatment options.
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
A University of Sydney study reveals how DNA origami can build programmable nanostructures, with promising applications in targeted drug delivery and nanorobotics.
CNIC researchers have identified a mechanism in fat cells that helps them safely store excess fat, offering new insights for combating obesity and related metabolic diseases.
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
Five distinct CRC prognostic subtypes were identified, which could revolutionise the way CRC is diagnosed and treated.